Universal Subsidized Continuous Glucose Monitoring Funding for Young People With Type 1 Diabetes : Uptake and Outcomes Over 2 Years, a Population-Based Study
© 2022 by the American Diabetes Association..
OBJECTIVE: Continuous glucose monitoring (CGM) is increasingly used in type 1 diabetes management; however, funding models vary. This study determined the uptake rate and glycemic outcomes following a change in national health policy to introduce universal subsidized CGM funding for people with type 1 diabetes aged <21 years.
RESEARCH DESIGN AND METHODS: Longitudinal data from 12 months before the subsidy until 24 months after were analyzed. Measures and outcomes included age, diabetes duration, HbA1c, episodes of diabetic ketoacidosis and severe hypoglycemia, insulin regimen, CGM uptake, and percentage CGM use. Two data sources were used: the Australasian Diabetes Database Network (ADDN) registry (a prospective diabetes database) and the National Diabetes Service Scheme (NDSS) registry that includes almost all individuals with type 1 diabetes nationally.
RESULTS: CGM uptake increased from 5% presubsidy to 79% after 2 years. After CGM introduction, the odds ratio (OR) of achieving the HbA1c target of <7.0% improved at 12 months (OR 2.5, P < 0.001) and was maintained at 24 months (OR 2.3, P < 0.001). The OR for suboptimal glycemic control (HbA1c ≥9.0%) decreased to 0.34 (P < 0.001) at 24 months. Of CGM users, 65% used CGM >75% of time, and had a lower HbA1c at 24 months compared with those with usage <25% (7.8 ± 1.3% vs. 8.6 ± 1.8%, respectively, P < 0.001). Diabetic ketoacidosis was also reduced in this group (incidence rate ratio 0.49, 95% CI 0.33-0.74, P < 0.001).
CONCLUSIONS: Following the national subsidy, CGM use was high and associated with sustained improvement in glycemic control. This information will inform economic analyses and future policy and serve as a model of evaluation diabetes technologies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:45 |
|---|---|
| Enthalten in: |
Diabetes care - 45(2022), 2 vom: 01. Feb., Seite 391-397 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Johnson, Stephanie R [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Blood Glucose |
|---|
| Anmerkungen: |
Date Completed 09.03.2022 Date Revised 07.12.2022 published: Print figshare: 10.2337/figshare.16940740 Citation Status MEDLINE |
|---|
| doi: |
10.2337/dc21-1666 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM334096804 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM334096804 | ||
| 003 | DE-627 | ||
| 005 | 20231225223009.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2337/dc21-1666 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1113.xml |
| 035 | |a (DE-627)NLM334096804 | ||
| 035 | |a (NLM)34872983 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Johnson, Stephanie R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Universal Subsidized Continuous Glucose Monitoring Funding for Young People With Type 1 Diabetes |b Uptake and Outcomes Over 2 Years, a Population-Based Study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.03.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a figshare: 10.2337/figshare.16940740 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 by the American Diabetes Association. | ||
| 520 | |a OBJECTIVE: Continuous glucose monitoring (CGM) is increasingly used in type 1 diabetes management; however, funding models vary. This study determined the uptake rate and glycemic outcomes following a change in national health policy to introduce universal subsidized CGM funding for people with type 1 diabetes aged <21 years | ||
| 520 | |a RESEARCH DESIGN AND METHODS: Longitudinal data from 12 months before the subsidy until 24 months after were analyzed. Measures and outcomes included age, diabetes duration, HbA1c, episodes of diabetic ketoacidosis and severe hypoglycemia, insulin regimen, CGM uptake, and percentage CGM use. Two data sources were used: the Australasian Diabetes Database Network (ADDN) registry (a prospective diabetes database) and the National Diabetes Service Scheme (NDSS) registry that includes almost all individuals with type 1 diabetes nationally | ||
| 520 | |a RESULTS: CGM uptake increased from 5% presubsidy to 79% after 2 years. After CGM introduction, the odds ratio (OR) of achieving the HbA1c target of <7.0% improved at 12 months (OR 2.5, P < 0.001) and was maintained at 24 months (OR 2.3, P < 0.001). The OR for suboptimal glycemic control (HbA1c ≥9.0%) decreased to 0.34 (P < 0.001) at 24 months. Of CGM users, 65% used CGM >75% of time, and had a lower HbA1c at 24 months compared with those with usage <25% (7.8 ± 1.3% vs. 8.6 ± 1.8%, respectively, P < 0.001). Diabetic ketoacidosis was also reduced in this group (incidence rate ratio 0.49, 95% CI 0.33-0.74, P < 0.001) | ||
| 520 | |a CONCLUSIONS: Following the national subsidy, CGM use was high and associated with sustained improvement in glycemic control. This information will inform economic analyses and future policy and serve as a model of evaluation diabetes technologies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Blood Glucose |2 NLM | |
| 650 | 7 | |a Glycated Hemoglobin A |2 NLM | |
| 650 | 7 | |a Hypoglycemic Agents |2 NLM | |
| 650 | 7 | |a Insulin |2 NLM | |
| 700 | 1 | |a Holmes-Walker, Deborah J |e verfasserin |4 aut | |
| 700 | 1 | |a Chee, Melissa |e verfasserin |4 aut | |
| 700 | 1 | |a Earnest, Arul |e verfasserin |4 aut | |
| 700 | 1 | |a Jones, Timothy W |e verfasserin |4 aut | |
| 700 | 0 | |a ADDN Study Group: |e verfasserin |4 aut | |
| 700 | 1 | |a Craig, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Anderson, Kym |e verfasserin |4 aut | |
| 700 | 1 | |a Ambler, Geoff |e verfasserin |4 aut | |
| 700 | 1 | |a Barrett, Helen |e verfasserin |4 aut | |
| 700 | 1 | |a Batch, Jenny |e verfasserin |4 aut | |
| 700 | 1 | |a Bergman, Philip |e verfasserin |4 aut | |
| 700 | 1 | |a Cameron, Fergus |e verfasserin |4 aut | |
| 700 | 1 | |a Colman, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Conwell, Louise |e verfasserin |4 aut | |
| 700 | 1 | |a Cooper, Chris |e verfasserin |4 aut | |
| 700 | 1 | |a Couper, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Davis, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a de Bock, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Donaghue, Kim |e verfasserin |4 aut | |
| 700 | 1 | |a Fairchild, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Fegan, Gerry |e verfasserin |4 aut | |
| 700 | 1 | |a Fourlanos, Spiros |e verfasserin |4 aut | |
| 700 | 1 | |a Glastras, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Gray, Leonie |e verfasserin |4 aut | |
| 700 | 1 | |a Hamblin, Shane |e verfasserin |4 aut | |
| 700 | 1 | |a Hofman, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Holmes-Walker, Dianne Jane |e verfasserin |4 aut | |
| 700 | 1 | |a Howard, Neville |e verfasserin |4 aut | |
| 700 | 1 | |a Jack, Michelle |e verfasserin |4 aut | |
| 700 | 1 | |a James, Steven |e verfasserin |4 aut | |
| 700 | 1 | |a Jefferies, Craig |e verfasserin |4 aut | |
| 700 | 1 | |a Johnson, Stephanie |e verfasserin |4 aut | |
| 700 | 1 | |a Kao, Jeff |e verfasserin |4 aut | |
| 700 | 1 | |a King, Bruce R |e verfasserin |4 aut | |
| 700 | 1 | |a Lafferty, Antony |e verfasserin |4 aut | |
| 700 | 1 | |a Martin, Michelle |e verfasserin |4 aut | |
| 700 | 1 | |a McCrossin, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Pascoe, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Paul, Ryan |e verfasserin |4 aut | |
| 700 | 1 | |a Pawlak, Dorota |e verfasserin |4 aut | |
| 700 | 1 | |a Peña, Alexia |e verfasserin |4 aut | |
| 700 | 1 | |a Price, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Price, Darrell |e verfasserin |4 aut | |
| 700 | 1 | |a Rodda, Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Simmons, David |e verfasserin |4 aut | |
| 700 | 1 | |a Sinnott, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Sive, Alan |e verfasserin |4 aut | |
| 700 | 1 | |a Smart, Carmel |e verfasserin |4 aut | |
| 700 | 1 | |a Stone, Monique |e verfasserin |4 aut | |
| 700 | 1 | |a Stranks, Steve |e verfasserin |4 aut | |
| 700 | 1 | |a Tham, Elaine |e verfasserin |4 aut | |
| 700 | 1 | |a Verge, Charles |e verfasserin |4 aut | |
| 700 | 1 | |a Ward, Glenn |e verfasserin |4 aut | |
| 700 | 1 | |a Wheeler, Ben |e verfasserin |4 aut | |
| 700 | 1 | |a Williams, Judy |e verfasserin |4 aut | |
| 700 | 1 | |a Woodhead, Helen |e verfasserin |4 aut | |
| 700 | 1 | |a Woolfield, Nick |e verfasserin |4 aut | |
| 700 | 1 | |a Zimmermann, Anthony |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diabetes care |d 1979 |g 45(2022), 2 vom: 01. Feb., Seite 391-397 |w (DE-627)NLM00042983X |x 1935-5548 |7 nnns |
| 773 | 1 | 8 | |g volume:45 |g year:2022 |g number:2 |g day:01 |g month:02 |g pages:391-397 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2337/dc21-1666 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 45 |j 2022 |e 2 |b 01 |c 02 |h 391-397 | ||